Skip to Main Content
Home Books Quick Answers: Pharmacy

Osteoporosis

SOURCE

Source: O’Connell MB, Borchet JS. Osteoporosis and Osteomalacia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=146068952. Accessed May 19, 2017.

DEFINITION

  • Bone disorder characterized by low bone mineral density (BMD), impaired bone architecture, and compromised bone strength predisposing to increased fracture risk.

ETIOLOGY

  • Genetics.

  • Diet.

  • Lifestyle.

  • Hormonal status.

  • Diseases.

  • Medications (Table 1)

  • Aging.

TABLE 1.Select Medications Associated with Increased Bone Loss and/or Fracture Risk
View Table||Download (.pdf)
TABLE 1. Select Medications Associated with Increased Bone Loss and/or Fracture Risk
Medications Comments
Anticonvulsant therapy (phenytoin, carbamazepine, phenobarbital, and valproic acid) ↓ BMD and ↑ fracture risk; increased vitamin D metabolism leading to low 25(OH) vitamin D concentrations

Antiretroviral therapy (ART)

 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) (zidovudine, didanosine, lamivudine, and tenofovir)

 Protease inhibitors (PI) (nelfinavir, indinivir, saquinavir, ritonavir, and lopinavir)

 ↓ BMD (NRTIs > PI), no fracture data; increased osteoclast activity and decreased osteoblast activity
Aromatase inhibitors (eg, letrozole and anastrozole) ↓ BMD and ↑ fracture risk; reduced estrogen concentrations
Canagliflozin ↓ BMD and ↑ fracture risk (FDA reviewing SLGT2 inhibitor class of medications)
Furosemide ↑ fracture risk; increased calcium renal elimination
Glucocorticoids (long-term oral therapy) ↓ BMD and ↑ fracture risk; increased bone resorption and decreased bone formation; dose and duration dependent; see special populations section
Gonadotropin-releasing hormone agonists or analogs (eg, leuprolide and goserelin) ↓ BMD and ↑ fracture risk; decreased sex hormone production
Heparin (unfractionated, UFH) or low molecular weight heparin (LMWH) ↓ BMD and ↑ fracture risk (UFH >>> LMWH) with long-term use (eg > 6 months); decreased osteoblast replication and increased osteoclast function
Medroxyprogesterone acetate depot administration ↓ BMD, no fracture data; possible BMD recovery with discontinuation; decreased estrogen concentrations
Proton pump inhibitor therapy (long-term therapy) ↓ BMD and ↑ fracture risk; possible calcium malabsorption secondary to acid suppression for carbonate salts
Selective serotonin reuptake inhibitors ↓ BMD and ↑ fracture risk; decreased osteoblast activity
Thiazolidinediones (pioglitazone and rosiglitazone) ↓ BMD and ↑ fracture risk; decreased osteoblast function
Thyroid—excessive supplementation ↓ BMD and ↑ fracture risk; risk increases with TSH concentration < 0.1 mIU/L; possible increase in bone resorption
Vitamin A—excessive intake (> 1.5 mg of retinol form) ↓ BMD and ↑ fracture risk; decreased osteoblast activity and increased osteoclast activity

BMD, bone mineral density; TSH, thyroid-stimulating hormone; DXA, dual-energy X-ray absorptiometry.

Reprinted with permission from DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017.

PATHOPHYSIOLOGY

  • Men and women begin to lose bone mass starting in third or fourth decade because of reduced bone formation.

  • Estrogen deficiency during menopause increases osteoclast activity, increasing bone resorption more than formation.

  • Etiology of ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close